載入中
NASDAQHealthcareBiotechnology
最新資料
US$11.31
−US$0.03 · -0.26%
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
前收盤價
US$11.31
−US$0.03 · -0.26%
盤前
US$11.21
−US$0.10 · -0.88%
10月8日 上午9:16 ET
盤中時間採用ET。市場資料可能有所延遲。
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
日內區間
目前US$11.31
52週區間
目前US$11.31
盤中時間採用ET。市場資料可能有所延遲。
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
日內區間
目前US$11.31
52週區間
目前US$11.31
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | — | 100萬 USD | 760萬 USD |
| 銷貨成本 | — | — | — | 10萬 USD | 20萬 USD |
| 毛利 | — | — | — | 90萬 USD | 740萬 USD |
| 研究與開發 | 1602.2萬 USD | 1909.6萬 USD | 2400.7萬 USD | 3026.8萬 USD | 2137.4萬 USD |
| 銷售、一般及管理費用 | 1225.2萬 USD | 1241.7萬 USD | 1386.2萬 USD | 1258.2萬 USD | 1132萬 USD |
| 營業費用 | 2827.4萬 USD | 3151.3萬 USD | 3786.9萬 USD | 4285萬 USD | 3269.4萬 USD |
| 利息收入 | 141.1萬 USD | 63.2萬 USD | 52.5萬 USD | 31.7萬 USD | 6000 USD |
| 折舊和攤銷 | — | 3151.3萬 USD | 3786.9萬 USD | 45.7萬 USD | 127.3萬 USD |
| 營業利益 | −2827.4萬 USD | −3151.3萬 USD | −3786.9萬 USD | −4195萬 USD | −2529.4萬 USD |
| 淨利 | −2686.3萬 USD | −3088.1萬 USD | −3734萬 USD | −4130.1萬 USD | −2069.9萬 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$35.00
上漲空間 209.46%價格歷史記錄不可用
最高：US$35.00平均的：US$35.00最低：US$35.00報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P Biotech ETFXBI6730.15萬0.65%100.75億 USD0.35%US$150.23-0.44%
iShares Russell 2000 ETFIWM5962.28萬0.08%785.63億 USD0.19%US$277.7-1.29%
Vanguard Extended Market ETFVXF2885.59萬0.03%954億 USD0.05%US$233.49-1.56%
iShares Russell 2000 Growth ETFIWO2134.7萬0.15%142.49億 USD0.24%US$355.37-1.43%
Vanguard Russell 2000 ETFVTWO1447.04萬0.08%180億 USD0.06%US$112.21-1.26%
Schwab U.S. Small-Cap ETFSCHA1189.23萬0.05%216.99億 USD0.03%US$32.61-1.47%
Vanguard Health Care ETFVHT800.66萬0.04%220億 USD0.09%US$315.31+0.78%
iShares Micro-Cap ETFIWC714.43萬0.54%13.33億 USD0.60%US$183.36-1.09%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTiShares Micro-Cap ETFIWCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
